Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Thrombosis Stories

2011-12-12 09:45:00

TOKYO and SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty, when compared to enoxaparin. Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis (DVT) and pulmonary...

2011-12-08 13:54:00

DENVER, Dec. 8, 2011 /PRNewswire-USNewswire/ -- Deep vein thrombosis (DVT) is a blood clot in the deep veins in the legs. These clots can break loose and travel to the lungs, causing a potentially fatal pulmonary embolism (PE). Even when they don't, they can cause permanent damage to the leg veins that results in long-term pain, swelling, and disability of the leg. (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20110303/DC58830LOGO</font>) Deep vein...

2011-12-05 02:00:00

LONDON, December 5, 2011 /PRNewswire/ -- - Atrial Fibrillation (AF) will affect 1 in 4 people in the UK and increases the risk of stroke by nearly 500%; the number of AF patients in the UK is expected to more than double by 2050 - AF is vastly under-treated, only 18 per cent of UK patients with AF receive treatment that adequately reduces their elevated risk of stroke - Adherence to current treatment guidelines and routine pulse checks in primary care could prevent...

2011-11-30 14:45:00

RICHMOND, Va., Nov. 30, 2011 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. (HDL, Inc.) announced today that medical advisory board member Michael F. Richman M.D., F.A.C.S., founder of the Center for Cholesterol Management and The Elite Laser Vein Center in Los Angeles, has initiated a study that will analyze the relevance of MTHFR polymorphisms in venous disease with or without concomitant thrombosis. It has been reported that a mutation in the gene encoding...

2011-11-16 07:30:00

NATICK, Mass., Nov. 16, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin America. The novel device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. The WATCHMAN LAA Closure Device is intended to prevent embolization of thrombi that may form in...

2011-11-14 14:02:00

BASKING RIDGE, N.J., Nov. 14, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announces one poster presentation and two oral presentations at the American Heart Association (AHA) Scientific Sessions meeting on November 14, 2011 during the 9:00 a.m. - 5:00 p.m. EST session. All three presentations highlight results from Regado's pipeline of antithrombotic agents for the treatment of...

2011-11-08 06:47:39

(Ivanhoe Newswire) — Drospirenone-containing oral birth control pills are linked to a significantly higher risk of blood clots, both deep vein thrombosis and pulmonary embolism, according to this study. All oral contraceptives are associated with a higher risk of blood clots, but there is conflicting information about the risk of adverse events with drospirenone. Many previous studies have evaluated risks of second- and third-generation contraceptives, which both contain derivatives...

2011-11-07 16:50:40

The use of drospirenone-containing oral birth control pills is linked to a significantly higher risk of blood clots, both deep vein thrombosis and pulmonary embolism, according to an article in the Canadian Medical Association Journal. All oral contraceptives are associated with a higher risk of blood clots, but there is conflicting information about the risk of adverse events with drospirenone. Many previous studies have evaluated risks of second- and third-generation contraceptives,...

2011-11-07 12:59:51

Dual imaging approach could improve diagnosis, treatment of coronary artery disease A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents. In their report receiving early online release in Nature Medicine, Massachusetts General Hospital (MGH) investigators describe using an intra-arterial...

2011-11-04 12:59:00

SILVER SPRING, Md., Nov. 4, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20090824/FDALOGO</font>) Atrial fibrillation occurs in more than 2 million Americans and is one of the most common types of abnormal heart...